

**SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP06587/2021 (Lineage B.1.621.1; Mu Variant)**

**Catalog No. NR-56225**

**Product Description:**

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MD-HP06587/2021 was isolated from a human on June 15, 2021, in Maryland, USA. NR-56225 lot 70048750 was produced by infecting *Homo sapiens* lung adenocarcinoma epithelial cells (Calu-3; ATCC® HTB-55™) with the deposited material and incubating in Eagle's Minimum Essential Medium (ATCC® 30-2003™) supplemented with 2% fetal bovine serum (ATCC® 30-2020™) for 3 days at 37°C with 5% CO<sub>2</sub>. The cells and supernatant were spin-clarified at 1500 × g for 10 minutes at 4°C.

**Passage History:**

V(1)/C(1) (Johns Hopkins University/BEI Resources); V = *Cercopithecus aethiops* kidney cells; C = Calu-3

**Lot: 70048750**

**Manufacturing Date: 08NOV2021**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: [Contact@BEIResources.org](mailto:Contact@BEIResources.org). We try to respond to feedback within 24 hours.

| TEST  | SPECIFICATIONS  | RESULTS   |
|---|---|---|
| Identification by Infectivity in Calu-3 Cells   | Cell rounding and detachment  | Cell rounding and detachment  |
| Next-Generation Sequencing (NGS) of Complete Genome Using Illumina® iSeq™ 100 Platform<br>(Refer to Appendix I for NGS information)   | ≥ 98% identity with isolate hCoV-19/USA/MD-HP06587/2021 (GISAID: EPI_ISL_3243079)       | 99.99% identity with isolate hCoV-19/USA/MD-HP06587/2021 (GISAID: EPI_ISL_3243079)      |
| Titer by TCID <sub>50</sub> Assay in Calu-3 Cells by Cytopathic Effect <sup>1</sup><br>(7 days at 37°C and 5% CO <sub>2</sub> )   | Report results  | 2.4 × 10 <sup>6</sup> TCID <sub>50</sub> per mL <sup>2</sup>                            |
| <b>Sterility (21-day incubation)</b><br>Harpo's HTYE broth, 37°C and 26°C, aerobic <sup>3</sup><br>Trypticase Soy broth, 37°C and 26°C, aerobic<br>Sabouraud broth, 37°C and 26°C, aerobic<br>Sheep blood agar, 37°C, aerobic<br>Sheep blood agar, 37°C, anaerobic<br>Thioglycollate broth, 37°C, anaerobic<br>DMEM with 10% FBS, 37°C, aerobic | No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth | No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth |
| <b>Mycoplasma Contamination</b><br>Agar and broth culture (14-day incubation at 37°C)<br>DNA detection by PCR of extracted Test Article nucleic acid  | None detected<br>None detected  | None detected<br>None detected  |

<sup>1</sup>The Tissue Culture Infectious Dose 50% (TCID<sub>50</sub>) endpoint is the 50% infectious endpoint in cell culture. The TCID<sub>50</sub> is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD<sub>50</sub>) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID<sub>50</sub> provides a measure of the titer (or infectivity) of a virus preparation.

<sup>2</sup>Titer was determined by cytopathic effects (CPE) and completed in triplicate (1.6 × 10<sup>6</sup> per mL, 2.8 × 10<sup>6</sup> per mL and 2.8 × 10<sup>6</sup> per mL). The average of the three values is reported.

<sup>3</sup>Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

/Sonia Bjorum Brower/  
Sonia Bjorum Brower  
 Technical Manager or designee, ATCC Federal Solutions

19 AUG 2022

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.  
 You are authorized to use this product for research use only. It is not intended for human use.



**APPENDIX I: NGS Information for NR-56225 lot 70048750**

Sequence analysis using AMGP readsQC-illumina.py pipeline and variant callers LoFreq version: 2.1.5 and freebayes version: v1.3.1-dirty resulted in the discovery of one SNP when compared to the reference sequence from GISAID EPI\_ISL\_3243079 (see Table I below). Additionally, both the reference sequence EPI\_ISL\_3243079 and NR-56225 lot 70048750 contained thirty-three SNPs, one insertion (INS) and one deletion (DEL) when compared to GenBank MN908947 (SARS-CoV-2, isolate Wuhan-Hu-1, complete genome) (see Table II below). Quality scores over 60 indicate it is improbable that the variant call is incorrect.

**Table I: Variants with different nucleotides between NR-56225 lot 70048750 and reference sequence EPI\_ISL\_3243079**

| Variant Type | Variant Position and Identified Alternative Base | Coverage | Length of Variant | Frequency of Variant | Gene (Region)  | Amino Acid Mutation |
|--------------|--|----------|-------------------|----------------------|----------------|---------------------|
| SNP          | t14679c  | 1583     | 1                 | 6.0013%              | ORF1ab (nsp12) | Silent mutation     |

**Table II: Variants with different nucleotides between NR-56225 lot 70048750 and GenBank MN908947.3 (SARS-CoV-2, isolate Wuhan-Hu-1, complete genome)**

| Variant Type | Variant Position and Identified Alternative Base | Coverage <sup>1</sup> | Length of Variant | Frequency of Variant <sup>1</sup> | Gene (Region)  | Amino Acid Mutation |
|--------------|--|-----------------------|-------------------|-----------------------------------|----------------|---------------------|
| SNP          | c241t  | N/A                   | 1                 | 100.0000%                         | 5'UTR          | Untranslated        |
| SNP          | a1818g   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp2)  | K338R               |
| SNP          | c3037t   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp3)  | Silent mutation     |
| SNP          | a3428g   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp3)  | T237A               |
| SNP          | c4878t   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp3)  | T720I               |
| SNP          | c5192t   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp3)  | Silent mutation     |
| SNP          | c6037t   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp3)  | Silent mutation     |
| SNP          | t6842g   | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp3)  | S1375A              |
| SNP          | c10029t  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp4)  | T492I               |
| SNP          | a11451g  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp6)  | Q160R               |
| SNP          | a13057t  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp10) | Silent mutation     |
| SNP          | c14408t  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp12) | P323L               |
| SNP          | c17491t  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp13) | P419S               |
| SNP          | c17707t  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp13) | P491S               |
| SNP          | c18877t  | N/A                   | -9                | 100.0000%                         | ORF1ab (nsp14) | Silent mutation     |
| SNP          | t19035c  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp14) | Silent mutation     |
| SNP          | c20148t  | N/A                   | 1                 | 100.0000%                         | ORF1ab (nsp15) | Silent mutation     |

| Variant Type | Variant Position and Identified Alternative Base | Coverage <sup>1</sup> | Length of Variant | Frequency of Variant <sup>1</sup> | Gene (Region)                  | Amino Acid Mutation                |
|--------------|--|-----------------------|-------------------|-----------------------------------|--------------------------------|------------------------------------|
| SNP          | c21846t  | N/A                   | 1                 | 100.0000%                         | Spike                          | T95I                               |
| INS          | 21990[tac]21991                                  | N/A                   | +3                | 100.0000%                         | Spike                          | V143[T]Y144                        |
| SNP          | t21995a  | N/A                   | 1                 | 100.0000%                         | Spike                          | Y145N                              |
| SNP          | g22599a  | N/A                   | 1                 | 100.0000%                         | Spike                          | R346K                              |
| SNP          | g23012a  | N/A                   | 1                 | 100.0000%                         | Spike                          | E484K                              |
| SNP          | a23063t  | N/A                   | 1                 | 100.0000%                         | Spike                          | N501Y                              |
| SNP          | a23403g  | N/A                   | 1                 | 100.0000%                         | Spike                          | D614G                              |
| SNP          | c23604a  | N/A                   | 1                 | 100.0000%                         | Spike                          | P681H                              |
| SNP          | g24410a  | N/A                   | 1                 | 100.0000%                         | Spike                          | D950N                              |
| SNP          | g25563t  | N/A                   | 1                 | 100.0000%                         | ORF3a                          | Q57H                               |
| DEL          | Δ26158-26161                                     | N/A                   | -4                | 100.0000%                         | ORF3a                          | V256I, N257Q, Δamino acids 258-275 |
| SNP          | a26492t  | N/A                   | 1                 | 100.0000%                         | Intergenic - Envelope/Membrane | Untranslated                       |
| SNP          | c27925a  | N/A                   | 1                 | 100.0000%                         | ORF8                           | T11K                               |
| SNP          | c28005t  | N/A                   | 1                 | 100.0000%                         | ORF8                           | P38S                               |
| SNP          | c28093t  | N/A                   | 1                 | 100.0000%                         | ORF8                           | S67F                               |
| SNP          | a28272t  | N/A                   | 1                 | 100.0000%                         | Intergenic - ORF8/Nucleocapsid | Untranslated                       |
| SNP          | c28887t  | N/A                   | 1                 | 100.0000%                         | Nucleocapsid                   | T250I                              |
| SNP          | g29779t  | N/A                   | 1                 | 100.0000%                         | 3'UTR                          | Untranslated                       |

<sup>1</sup>Coverage for all variants in Table II is listed as 'N/A'. There is no read coverage information for these variants because the sample reads are only mapped to the reference sequence and not to the SARS-CoV-2, Wuhan-Hu-1 isolate sequence (GenBank MN908947), but that does not mean these areas lack for coverage. All variants in Table II are mismatches in between the reference sequence and the SARS-CoV-2, Wuhan-Hu-1 sequence, so these variants will be assigned a frequency of 100% and will therefore be majority SNPs.